To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: Europe Approves Expanded Indications For Cystistat (Hyaluronic Acid) URL: http://www.pslgroup.com/dg/1E01D6.htm Doctor's Guide September 7, 2000
LONDON, ON -- September 7, 2000 -- Bioniche Life Sciences Inc, a fully integrated Canadian biopharmaceutical company serving both the human and animal health markets, announced receipt of approval to expand the indications for one of its lead products, Cystistat® (hyaluronic acid), in Europe. The new indications include radiation cystitis and cystitis caused by infections, trauma, urolithiasis, urinary retention, and neoplasia. "The European approval for these additional indications marks an important milestone in our development of Cystistat in conjunction with our on-going efforts to secure a U.S. registration," said Dr. Vincent A. Salvatori, Senior Vice President, Clinical Operations. "This approval also represents an important new alternative therapy for urologists and will enhance our reputation as a leading provider of urological therapeutics." "These expanded indications encompass all forms of cystitis and provide broader opportunities for all of our existing European Cystistat marketing partners," remarked Albert Beraldo, Vice President of Business Development at Bioniche. "With a larger market profile, Bioniche will be better positioned to attract additional quality marketing partners in the remaining regions of Europe." Licensing and distribution agreements are currently in place throughout Europe including the UK, Italy, Scandinavia, Austria and Spain. Cystistat is Bioniche's patented treatment for Interstitial Cystitis (IC), a painful, debilitating bladder condition that afflicts approximately 1.5 million people worldwide. Manufactured from a highly purified hyaluronic-acid, Cystistat is instilled directly into the bladder where the drug helps to restore the glycosaminoglycan (GAG) layer. Cystistat is manufactured at the Company's FDA/ISO 9001 approved facility in Ireland and is currently approved for distribution in Canada and Europe. Related Link: Bioniche Life Sciences Inc. --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.